ライフサイエンスコーパス: acute lymphocytic leukemia

1 ia, primary myelofibrosis, and T- and B-cell acute lymphocytic leukemia.

2 unctions as a tumor suppressor in pre-B cell acute lymphocytic leukemia.

3 ically-derived curative therapy in childhood acute lymphocytic leukemia.

4 is widely expressed in AML and some cases of acute lymphocytic leukemia.

5 -old female patient with relapsed pre-B-cell acute lymphocytic leukemia.

6 ession of two LIM-only factors (LMOs) causes acute lymphocytic leukemia.

7 frequency of these translocations in T-cell acute lymphocytic leukemia.

8 for the prevention of central nervous system acute lymphocytic leukemia.

9 essentially absent in samples of chronic or acute lymphocytic leukemia.

10 ranscription factor involved in human T cell acute lymphocytic leukemia.

11 and pediatric acute myelogenous leukemia and acute lymphocytic leukemia.

12 patients with acute myelogenous leukemia or acute lymphocytic leukemia.

13 the age-frequency distribution of childhood acute lymphocytic leukemia.

14 is proposed and applied to a recent trial in acute lymphocytic leukemia.

15 ounterbalances the activating role of T-cell acute lymphocytic leukemia 1 (TAL1).

16 tors [Gata binding protein 1 (Gata1), T cell acute lymphocytic leukemia 1 protein (Tal1), and Erythro

17 The transcription factor TAL1 (T-cell acute lymphocytic leukemia 1) is critical for establishi

18 the principal hematopoietic regulator T-cell acute lymphocytic leukemia-1 (TAL1) is involved in regul

19 y elements across 200 kb of the mouse T-cell acute lymphocytic leukemia-1 (Tal1) locus, and, in addit

20 topoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphoc

21 c acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myeloge

22 cute myelogenous leukemia (AML) (n = 39) and acute lymphocytic leukemia (ALL) (n = 11) patients who h

23 t was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with re

24 omal translocation in particular subtypes of acute lymphocytic leukemia (ALL) and acute myelogenous l

25 We report a case of a young woman with acute lymphocytic leukemia (ALL) and prolonged neutropen

26 ute myelo-genous leukemia (AML), rarely with acute lymphocytic leukemia (ALL) and with therapy relate

27 ladelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-dri

28 The MTHFR 677TT genotype was lower among 71 acute lymphocytic leukemia (ALL) cases compared with 114

29 as also observed with a p185BCR-ABL-positive acute lymphocytic leukemia (ALL) cell line generated fro

30 aEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-typ

31 iety of acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cell lines, cellular le

32 f either mTOR-containing complex is toxic to acute lymphocytic leukemia (ALL) cells and identify 2 pr

33 MLL-AF4 acute lymphocytic leukemia (ALL) has a poor prognosis.

34 ML) or Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) have achieved clinical

35 Acute lymphocytic leukemia (ALL) is the most prevalent p

36 tely 10% of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients harbor a trans

37 nd beta1i is cytotoxic to primary cells from acute lymphocytic leukemia (ALL) patients.

38 The t(1;19) translocation of pre-B cell acute lymphocytic leukemia (ALL) produces E2a-Pbx1, a ch

39 ed complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myel

40 tation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring th

41 orts a role for infection in the etiology of acute lymphocytic leukemia (ALL), and the involvement of

42 rical progress in the treatment of pediatric acute lymphocytic leukemia (ALL), in which increasingly

43 nical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma,

44 transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leu

45 rates p190(Bcr-Abl) which is mostly found in acute lymphocytic leukemia (ALL), whereas fusion of the

46 scription start site of p57KIP2 was found in acute lymphocytic leukemia (ALL)-derived cell lines.

47 c and 50% of pre-B-cell receptor (preBCR(+)) acute lymphocytic leukemia (ALL).

48 myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL).

49 nic myeloid leukemia (CML) and some cases of acute lymphocytic leukemia (ALL).

50 on patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).

51 improvement in the outcome of patients with acute lymphocytic leukemia (ALL).

52 blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL).

53 (HPRT)-reporter gene in children treated for acute lymphocytic leukemia (ALL).

54 hemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL).

55 lapsed Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL).

56 his mutant also caused a simultaneous B-cell acute lymphocytic leukemia (ALL).

57 ;21) chromosomal translocation inB-precursor acute lymphocytic leukemia (ALL).

58 98C were associated with lower risk of adult acute lymphocytic leukemia (ALL).

59 myelogenous leukemia (AML, 42 patients) and acute lymphocytic leukemia (ALL, 18 patients).

60 ewly diagnosed non-Hodgkin's lymphoma (25%), acute lymphocytic leukemia (ALL; 53%), and chronic-phase

61 ukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/

62 ts with relapsed/refractory pediatric B-cell Acute Lymphocytic Leukemia (ALL; n = 31) or adult B-cell

63 c myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL).

64 ronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well

65 Six hundred thirty-eight patients (307 with acute lymphocytic leukemia [ALL], 311 with non-Hodgkin's

66 , the most common translocation in pediatric acute lymphocytic leukemias, also disrupts CBFA2.

67 vival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered con

68 tigen receptors to treat relapsed/refractory acute lymphocytic leukemia and cytotoxic T-lymphocyte-as

69 kemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogeno

70 ortality, colon and breast cancer, childhood acute lymphocytic leukemia, and acute myocardial infarct

71 healthy donors, acute myelogenous leukemias, acute lymphocytic leukemias, and myelodysplastic syndrom

72 th colon cancer, breast cancer, or childhood acute lymphocytic leukemia; and 30-day age-standardized

73 itt's lymphoma, analysis of pediatric B-cell acute lymphocytic leukemia (B-ALL) samples showed increa

74 CAR T-cell therapy against precursor B-cell acute lymphocytic leukemia (B-ALL).

75 in polyglutamates of methotrexate (MTX) than acute lymphocytic leukemia blasts when incubated with th

76 ic Malignancies, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia (C) RSNA, 2025.

77 e empirically derived treatment of pediatric acute lymphocytic leukemia, can consistently achieve cur

78 tory potential of salinosporamide A in human acute lymphocytic leukemia CCRF-CEM cells, and its 10-fo

79 not block cell cycle progression in a T-cell acute lymphocytic leukemia cell line (CEM) sensitive to

80 f low cell density cultures of a human pre-B-acute lymphocytic leukemia cell line, SMS-SB: no other c

81 ay and the consequences of its inhibition in acute lymphocytic leukemia cells (ALL).

82 ld contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and expl

83 protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconst

84 ity or resistance of glioblastoma and B-cell acute lymphocytic leukemia cells.

85 Inspection of rare pedigrees transmitting acute lymphocytic leukemia, chronic myelogenous leukemia

86 hat causes most chronic myelogenous and some acute lymphocytic leukemias (CML and ALL) in humans.

87 , RPMI-8392, established from a patient with acute lymphocytic leukemia, contain two major forms of c

88 kemia patients (20 acute myeloid leukemia, 1 acute lymphocytic leukemia) for the expression of BCRP m

89 5-year survival rate for White children with acute lymphocytic leukemia in the 5% highest-income US c

90 A pre-B-cell acute lymphocytic leukemia miR, miR-143-3p, and a T-cell

91 Similar to acute lymphocytic leukemia, MM seems to include several

92 We used the Jurkat T cell acute lymphocytic leukemia model to characterize the rol

93 ses on patients with acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, non-Hodgki

94 (n = 6), acute myeloid leukemia (n = 5), and acute lymphocytic leukemia (n = 5) exhibited low to medi

95 is especially effective in the treatment of acute lymphocytic leukemia, non-Hodgkin's lymphoma, and

96 ry B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas.

97 leukemia and a small number of patients with acute lymphocytic leukemia or myelodysplastic syndrome.

98 gnancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome)

99 We performed a retrospective study on 105 acute lymphocytic leukemia patients treated with 12 Gy t

100 ETV6-RUNX1 carriers develop precursor B-cell acute lymphocytic leukemia (pB-ALL), the underlying gene

101 xpression of Stem cell leukemia (Scl)/T-cell acute lymphocytic leukemia protein 1 rescued hemogenic v

102 led minimal residual disease in hyperdiploid acute lymphocytic leukemia, providing "proof of concept.

103 MG-I mRNA and protein are increased in human acute lymphocytic leukemia samples.

104 demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutat

105 rom healthy controls or patients with T cell acute lymphocytic leukemia (T-ALL), demonstrated reducti

106 re examined in 33 adult patients with T-cell acute lymphocytic leukemia (T-ALL).

107 ent in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL).

108 some cases of acute myelocytic leukemia and acute lymphocytic leukemia, the bcr-abl oncogene is invo

109 mens from a 23-year-old male with refractory acute lymphocytic leukemia were obtained at 3 different

110 who had received chemotherapy for B-lineage acute lymphocytic leukemia were studied to determine whe